AIDS Vaccines

Publication Title: 
Psychology, Health & Medicine

The Health Belief Model provides a framework to understand motivators for volunteering for medical research. Motivators can take the form of social and personal benefits. In this systematic review of review articles, we contrast motivators of participation in actual cancer trials to those in actual HIV vaccine trials. We retrieved eight review articles from 2000 to 2012 examining motivators to participation in actual cancer trials.

Dhalla, Shayesta
Poole, Gary
Publication Title: 
AIDS (London, England)

OBJECTIVE: To determine the willingness of populations at high risk of HIV-1 infection to participate in HIV vaccine efficacy trials, determine factors influencing decision-making, and evaluate knowledge levels of vaccine trial concepts. DESIGN: Cross-sectional study. METHODS: HIV-1-negative homosexual men, male and female injecting drug users and non-injecting women at heterosexual risk were recruited in eight cities in the United States (n=4892).

Koblin, B. A.
Heagerty, P.
Sheon, A.
Buchbinder, S.
Celum, C.
Douglas, J. M.
Gross, M.
Marmor, M.
Mayer, K.
Metzger, D.
Seage, G.
Publication Title: 
Journal of Acquired Immune Deficiency Syndromes (1999)

We assessed willingness to participate in an HIV recombinant gp120 bivalent subtypes B/E candidate vaccine efficacy trial among 193 injection drug users (IDUs) attending drug treatment clinics in Bangkok, Thailand. IDUs previously enrolled in a prospective cohort study were invited to group sessions describing a potential trial, then completed questionnaires assessing comprehension and willingness to participate.

MacQueen, K. M.
Vanichseni, S.
Kitayaporn, D.
Lin, L. S.
Buavirat, A.
Naiwatanakul, T.
Raktham, S.
Mock, P.
Heyward, W. L.
Des Jarlais, D. C.
Choopanya, K.
Mastro, T. D.
Publication Title: 
Journal of Acquired Immune Deficiency Syndromes (1999)

Evaluation of HIV vaccines requires high-risk individuals willing to participate in a vaccine trial. We investigated the willingness to participate in HIV vaccine trials of initially HIV-seronegative homosexual men enrolled in an HIV seroincidence cohort study. Of 815 initially HIV-seronegative participants, 569 (69.8%) reported willingness to participate in an HIV vaccine trial. Altruism was the primary reason given for wanting to participate.

PÈrissÈ, A. R.
Schechter, M.
Moreira, R. I.
do Lago, R. F.
Santoro-Lopes, G.
Harrison, L. H.
Publication Title: 
Sexually Transmitted Infections

OBJECTIVES: Willingness to participate in HIV-1 vaccine trials and associated factors were investigated in a sample of 2670 Royal Thai Army conscripted recruits. METHODS: Self administered questionnaires were used. Data were collected during the final visit of a longitudinal cohort study of HIV-1 epidemiology. Cross sectional analysis of data from this visit was performed. RESULTS: 32% of the respondents reported they would "definitely" join an HIV-1 vaccine trial.

Jenkins, R. A.
Torugsa, K.
Markowitz, L. E.
Mason, C. J.
Jamroentana, V.
Brown, A. E.
Nitayaphan, S.
Publication Title: 
Journal of Acquired Immune Deficiency Syndromes (1999)

This study examined perceived risks, benefits, and desired information related to willingness to volunteer in preventive HIV vaccine trials. SAMPLE: Purposive sampling was used to select 90 participants among injecting drug users (Philadelphia, PA, U.S.A.); gay men (San Francisco, CA, U.S.A.); and black Americans (Durham, NC, U.S.A.). METHODS: A qualitative interview guide elicited perceived benefits, risks, and desired information relating to trial participation. Themes were developed from the transcribed texts and from freelists.

Strauss, R. P.
Sengupta, S.
Kegeles, S.
McLellan, E.
Metzger, D.
Eyre, S.
Khanani, F.
Emrick, C. B.
MacQueen, K. M.
Publication Title: 
Social Science & Medicine (1982)

HIV treatment for participants who become infected during HIV vaccine trials has been the focus of ethical controversy. The obligations of sponsors to ensure that participants have access to antiretrovirals have been a particular focus of this debate. This paper presents three arguments that have been made in this regard, and some of their limitations, in anticipation of HIV vaccine trials in South Africa.

Slack, C.
Stobie, M.
Milford, C.
Lindegger, G.
Wassenaar, D.
Strode, A.
Ijsselmuiden, C.
Publication Title: 

Successful conduct of HIV vaccine trials in a population of great cultural diversity like India could be a challenge. Concerns, knowledge gaps and willingness to participate in future HIV vaccine trials were studied among 349 patients attending three sexually transmitted infections clinics and one reproductive tract infections clinic. Overall willingness to volunteer for HIV vaccine trials was 48%. Women and men at risk of HIV infection were willing to participate in the HIV vaccine trials.

Sahay, Seema
Mehendale, Sanjay
Sane, Suvarna
Brahme, Radhika
Brown, Amishah
Charron, Karen
Beyrer, Chris
Bollinger, Robert
Paranjape, Ramesh
Publication Title: 
Journal of Interprofessional Care

We conducted Community-Based Participatory Research (CBPR), using a qualitative focus group design, to assess factors that might impact participation of high-risk impoverished adults in future HIV Vaccine Trials (HIVVTs). The participants were 40 homeless and low-income adults recruited from subsidized apartments and homeless shelters in Los Angeles. Findings revealed that the participants expressed both concerns and interest in future HIVVTs. Concerns centered on the impact of the vaccine on their physical health, the possibility of seroconverting and its associated stigma.

Nyamathi, Adeline
Koniak-Griffin, Deborah
Tallen, Louise
Gonz·lez-Figueroa, Evelyn
Levson, Lisa
Mosley, Yvonne
Dominick, Ernestina
Anderson, Nancy L. R.
Publication Title: 
Journal of Acquired Immune Deficiency Syndromes (1999)

BACKGROUND: Underrepresentation of ethnic minority communities limits the generalizability of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV vaccine trial participation among low-socioeconomic ethnic minority respondents at risk for HIV. METHODS: Six focus group interviews were conducted using a semistructured interview guide. Participants (N = 58, mean age = 36 years, 37% female, and 56% Latino/a and 35% African American) were recruited using venue-based sampling in Los Angeles.

Newman, Peter A.
Duan, Naihua
Roberts, Kathleen J.
Seiden, Danielle
Rudy, Ellen T.
Swendeman, Dallas
Popova, Svetlana


Subscribe to RSS - AIDS Vaccines